Abstract | BACKGROUND: OBJECTIVE: METHODS: Cerebrospinal fluid samples were collected from PD patients (n = 18), clinically diagnosed 4-repeat tauopathy patients; corticobasal syndrome (CBS) (n = 3) and PSP (n = 8); and pathologically diagnosed PSP (n = 8) and CBD patients (n = 7). Each patient set was compared to its appropriate control group consisting of age and gender matched individuals. Select lysosomal network protein levels were detected via Western blotting. Factor analysis was used to test the diagnostic sensitivity, specificity and accuracy of the select lysosomal network protein expression profiles. RESULTS: CONCLUSIONS:
|
Authors | Andrea Boman, Samuel Svensson, Adam Boxer, Julio C Rojas, William W Seeley, Anna Karydas, Bruce Miller, Katarina Kågedal, Per Svenningsson |
Journal | Journal of Parkinson's disease
(J Parkinsons Dis)
Vol. 6
Issue 2
Pg. 307-15
(04 02 2016)
ISSN: 1877-718X [Electronic] Netherlands |
PMID | 27061067
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers
- LAMP1 protein, human
- LAMP2 protein, human
- Lysosomal-Associated Membrane Protein 2
- Lysosome-Associated Membrane Glycoproteins
- MAP1LC3A protein, human
- Microtubule-Associated Proteins
- Vesicular Transport Proteins
- early endosome antigen 1
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers
(cerebrospinal fluid)
- Female
- Humans
- Lysosomal-Associated Membrane Protein 2
(cerebrospinal fluid)
- Lysosome-Associated Membrane Glycoproteins
(cerebrospinal fluid)
- Lysosomes
(metabolism)
- Male
- Microtubule-Associated Proteins
(cerebrospinal fluid)
- Middle Aged
- Parkinsonian Disorders
(cerebrospinal fluid, diagnosis)
- Supranuclear Palsy, Progressive
(cerebrospinal fluid, diagnosis)
- Tauopathies
(cerebrospinal fluid, diagnosis)
- Vesicular Transport Proteins
(cerebrospinal fluid)
|